ProCE Banner Activity

How VMAT2 Inhibitors Make Life-Changing Improvements for People With TD

Clinical Thought
The risk of tardive dyskinesia has been a barrier to treating patients with antipsychotics. Now, however, there are treatment options available to treat tardive dyskinesia. Stephen R. Saklad, PharmD, BCPP, discusses the VMAT2 inhibitors and how they have revolutionized how we think about tardive dyskinesia.

Released: November 28, 2022

Expiration: November 27, 2023

No longer available for credit.

Share

Faculty

Stephen R. Saklad

Stephen R. Saklad, PharmD, BCPP

Emeritus Clinical Professor
The University of Texas at Austin
College of Pharmacy
Division of Pharmacotherapy
UT Health San Antonio
School of Medicine
San Antonio, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Neurocrine Biosciences

Faculty Disclosure

Primary Author

Stephen R. Saklad, PharmD, BCPP

Emeritus Clinical Professor
The University of Texas at Austin
College of Pharmacy
Division of Pharmacotherapy
UT Health San Antonio
School of Medicine
San Antonio, Texas

Stephen R. Saklad, PharmD, BCPP: consultant/advisor/speaker: Neurocrine, Teva.